Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) - Total Liabilities
Based on the latest financial reports, Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) has total liabilities worth ₫870.62 Billion VND (≈ $33.08 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Binh Dinh Pharmaceutical and Medical Equ to evaluate the company's liquid asset resilience ratio.
Binh Dinh Pharmaceutical and Medical Equipment JSC - Total Liabilities Trend (2020–2025)
This chart illustrates how Binh Dinh Pharmaceutical and Medical Equipment JSC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see DBD current and non-current assets.
Binh Dinh Pharmaceutical and Medical Equipment JSC Competitors by Total Liabilities
The table below lists competitors of Binh Dinh Pharmaceutical and Medical Equipment JSC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AMIA Co. Ltd.
TW:8438
|
Taiwan | NT$1.15 Billion |
|
Bank Bumi Arta Tbk
JK:BNBA
|
Indonesia | Rp5.12 Trillion |
|
LB Semicon Inc
KQ:061970
|
Korea | ₩445.64 Billion |
|
Syscom Computer Engineering Co
TW:2453
|
Taiwan | NT$2.44 Billion |
|
Home Center Holdings Co.Ltd
KQ:060560
|
Korea | ₩293.88 Billion |
|
SHANGH.DAZ.PUBL.UTIL.YC 1
F:6WL
|
Germany | €12.99 Billion |
|
Fu Yu Property Co Ltd
TWO:4907
|
Taiwan | NT$5.81 Billion |
|
Duxton Water Ltd
AU:D2O
|
Australia | AU$20.63 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Binh Dinh Pharmaceutical and Medical Equipment JSC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See DBD equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Binh Dinh Pharmaceutical and Medical Equipment JSC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Binh Dinh Pharmaceutical and Medical Equipment JSC (2020–2025)
The table below shows the annual total liabilities of Binh Dinh Pharmaceutical and Medical Equipment JSC from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₫862.89 Billion ≈ $32.78 Million |
+43.08% |
| 2024-12-31 | ₫603.07 Billion ≈ $22.91 Million |
+8.45% |
| 2023-12-31 | ₫556.07 Billion ≈ $21.13 Million |
+2.86% |
| 2022-12-31 | ₫540.58 Billion ≈ $20.54 Million |
+29.03% |
| 2021-12-31 | ₫418.97 Billion ≈ $15.92 Million |
-6.64% |
| 2020-12-31 | ₫448.78 Billion ≈ $17.05 Million |
-- |
About Binh Dinh Pharmaceutical and Medical Equipment JSC
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company manufactures and trades in pharmaceuticals and medical equipment in Vietnam. It offers antibiotics; anticancer drugs; hemodialysis solutions; hepatobiliary drugs; analgesic and antipyretic drugs; drugs for muscles, bones, and joints; antihistamine anti-allergy drugs; ear, eye, nose, and throat drops; cardiovascular drugs; nervous … Read more